

Table 6. Preliminary *in vitro* anticancer results

Entry	Concentration(mg/mL)	Inhibition (%)±SD			
		gastric cancer	A549	MCF-7	Hela
1	0.78125	13.57±2.65	12.03±1.13	9.76±2.84	6.34±2.58
2	1.5625	16.38±1.91	15.99±2.77	31.90±4.79	11.73±0.94
3	3.125	26.54±1.48	24.02±2.41	35.54±3.46	12.49±3.12
4	6.25	39.90±2.26	34.98±1.69	35.61±2.55	19.61±2.72
5	12.5	44.64±2.41	41.89±4.76	47.20±4.59	23.62±3.01
6	25	64.30±2.80	51.79±2.48	52.87±2.57	34.66±3.38
7	50	61.32±5.32	93.21±2.24	27.93±3.89	85.33±3.03
8	100	27.38±2.63	78.92±2.53	26.33±4.13	77.54±2.08
IC ₅₀ (mg/mL)		48.47	11.47	763.14	23.77